We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urine-Based Molecular Test Detects Bladder Cancer Quickly and Accurately

By LabMedica International staff writers
Posted on 14 Mar 2023
Print article
Image: Researchers have developed a novel urine-based test for the non-invasive detection of bladder cancer (Photo courtesy of Nonacus)
Image: Researchers have developed a novel urine-based test for the non-invasive detection of bladder cancer (Photo courtesy of Nonacus)

Flexible cystoscopy, an invasive procedure involving the insertion of a camera into the bladder, is currently the main technique used to identify bladder cancer tumors. However, this process can be uncomfortable and expensive for patients, and the majority of these cystoscopies result in no abnormalities or malignancies being detected. Now, a new urine-based molecular test can rapidly and precisely detect bladder cancer, thereby streamlining diagnosis and minimizing the necessity for invasive procedures like cystoscopies.

A collaboration between the University of Birmingham (Birmingham, UK) researchers and liquid biopsy cancer detection and screening company Nonacus (Birmingham, UK) has resulted in a novel test for the non-invasive detection of bladder cancer. The GALEAS Bladder from Nonacus is a non-invasive, urine-based diagnostic test designed to provide a sample-to-report molecular triage for patients exhibiting symptoms of hematuria (blood in urine). The urine-based molecular biomarker provides a highly sensitive test that enables the rapid and precise detection of bladder cancer, thus enhancing diagnosis and eliminating the need for invasive cystoscopies.

The test combines highly sensitive liquid biopsy technology with a panel of biomarkers to detect the presence of bladder cancer by locating DNA from tumor cells in urine. The biomarker panel has been validated by the researchers in more than 600 patient samples from three UK clinical cohorts. Their analysis has shown the test to have a high diagnostic accuracy (sensitivity >90%, specificity >85%) across all grades and stages of bladder cancer. The test could potentially work across the entire bladder cancer patient pathway, reducing dependence on invasive cystoscopy and expensive imaging for non-muscle-invasive bladder cancer surveillance and minimal residual disease monitoring, as well as triage for hematuria.

“We are very excited to launch GALEAS Bladder,” said Chis Sale, CEO of Nonacus. “We are striving to develop a suite of meaningful non-invasive tools that can have real impact on the diagnosis and treatment of patients with suspected cancer. GALEAS Bladder represents the first in this pipeline, helping to improve patients' lives and reducing the burden of cystoscopy on overstretched clinics.”

Related Links:
University of Birmingham 
Nonacus

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more